Comparative study of GDNF delivery systems for the CNS: Polymer rods, encapsulated cells, and lentiviral vectors

Journal of Controlled Release

Volumn 87, Issue 1-3, 2003, Pages 107-115

  Bensadoun, Jean Charles ^a,b   De Almeida, Luis Pereira ^b,c   Fine, Eric G ^b   Tseng, Jack L ^b   Déglon, Nicole ^a,b   Aebischer, Patrick ^a,b  

^a EPFL   (Switzerland)

^b Laboratory of Cellular and Molecular Neurotherapies   (Switzerland)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cell encapsulation; CNS delivery; Lentiviral vectors; Neurotrophic factors; Polymer rods

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CELL ENCAPSULATION; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; GENETIC ENGINEERING; METHODOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0037458929     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00353-X     Document Type: Conference Paper

References (33)

1. Hefti F. Pharmacology of neurotrophic factors. Annu. Rev. Pharmacol. Toxicol. 37:1997;239-267.
2. Connor B., Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Rev. 27:1998;1-39.
3. Haller M.F., Saltzman W.M. Localized delivery of proteins in the brain: can transport be customized? Pharm. Res. 15:1998;377-385.
4. Aebischer P., Ridet J. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci. 24:2001;533-540.
5. Morse J.K., Wiegand S.J., Anderson K., You Y., Cai N., Carnahan J., Miller J., DiStefano P.S., Altar C.A., Lindsay R.M. Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. J. Neurosci. 13:1993;4146-4156.
6. Yan Q., Matheson C., Sun J., Radeke M.J., Feinstein S.C., Miller J.A. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp. Neurol. 127:1994;23-36.
7. Olson L., Nordberg A., von Holst H., Backman L., Ebendal T., Alafuzoff I., Amberla K., Hartvig P., Herlitz A., Lilja A., et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural Transm. Park. Dis. Dement. Sect. 4:1992;79-95.
8. Eriksdotter Jonhagen M., Nordberg A., Amberla K., Backman L., Ebendal T., Meyerson B., Olson L., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9:1998;246-257.
9. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., Mufson E.J., Penn R., Goetz C.G., Comella C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46:1999;419-424.
10. Anderson K.D., Alderson R.F., Altar C.A., DiStefano P.S., Corcoran T.L., Lindsay R.M., Wiegand S.J. Differential distribution of exogenous BDNF, NGF, and NT-3 in the brain corresponds to the relative abundance and distribution of high-affinity and low-affinity neurotrophin receptors. J. Comp. Neurol. 357:1995;296-317.
11. Rinsch C., Regulier E., Déglon N., Dalle B., Beuzard Y., Aebischer P. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum. Gene Ther. 8:1997;1881-1889.
12. Déglon N., Heyd B., Tan S.A., Joseph J.M., Zurn A.D., Aebischer P. Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum. Gene Ther. 7:1996;2135-2146.
13. Moens K., Heimberg H., Flamez D., Huypens P., Quartier E., Ling Z., Pipeleers D., Gremlich S., Thorens B., Schuit F. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes. 45:1996;257-261.
14. Hottinger A.F., Azzouz M., Déglon N., Aebischer P., Zurn A.D. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J. Neurosci. 20:2000;5587-5593.
15. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y.P., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z.D., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
16. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1998;Academic Press, London.
17. Hoffman D., Wahlberg L., Aebischer P. NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Exp. Neurol. 110:1990;39-44.
18. Tornqvist N., Björklund L., Almqvist P., Wahlberg L., Stromberg I. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease. Exp. Neurol. 164:2000;130-138.
19. Tseng J.L., Baetge E.E., Zurn A.D., Aebischer P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17:1997;325-333.
20. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., Widmer H.R., Zurn A.D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol. 149:1998;230-236.
21. Tseng J.L., Bruhn S.L., Zurn A.D., Aebischer P. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. NeuroReport. 9:1998;1817-1822.
22. Emerich D.F., Bruhn S., Chu Y., Kordower J.H. Cellular delivery of CNTF but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Huntington's disease. Cell Transplant. 7:1998;213-225.
23. Emerich D.F., Lindner M.D., Winn S.R., Chen E.Y., Frydel B.R., Kordower J.H. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16:1996;5168-5181.
24. Emerich D.F., Winn S.R., Hantraye P.M., Peschanski M., Chen E.Y., Chu Y., McDermott P., Baetge E.E., Kordower J.H. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature. 386:1997;395-399.
25. Mittoux V., Joseph J.M., Conde F., Palfi S., Dautry C., Poyot T., Bloch J., Deglon N., Ouary S., Nimchinsky E.A., Brouillet E., Hof P.R., Peschanski M., Aebischer P., Hantraye P. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum. Gene Ther. 11:2000;1177-1187.
26. Aebischer P., Schluep M., Déglon N., Joseph J.M., Hirt L., Heyd B., Goddard M., Hammang J.P., Zurn A.D., Kato A.C., Regli F., Baetge E.E. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2:1996;696-699.
27. Zurn A.D., Henry H., Schluep M., Aubert V., Winkel L., Eilers B., Bachmann C., Aebischer P. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant. 9:2000;471-484.
28. Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 9:1998;457-463.
29. Vigna E., Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2:2000;308-316.
30. Déglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira de Almeida L., Zufferey R., Trono D., Aebischer P. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11:2000;179-190.
31. Bensadoun J.C., Déglon N., Tseng J.L., Ridet J.L., Zurn A.D., Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioural improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164:2000;15-24.
32. Reiser J., Lai Z.N., Zhang X.Y., Brady R.O. Development of multigene and regulated lentivirus vectors. J. Virol. 74:2000;10589-10599.
33. Kafri T., van Praag H., Gage F.H., Verma I.M. Lentiviral vectors: regulated gene expression. Mol. Ther. 1:2000;516-521.